Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BL-B01D1 in recurrent or metastatic gynecologic malignancies and other solid tumors
CTR20230883Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in gynecological cancer, Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started Jun 2023; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
gynecological cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230883.